Cargando…
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
High quality protocols facilitate proper conduct, reporting, and external review of clinical trials. However, the completeness of trial protocols is often inadequate. To help improve the content and quality of protocols, an international group of stakeholders developed the SPIRIT 2013 Statement (Sta...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group Ltd.
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3541470/ https://www.ncbi.nlm.nih.gov/pubmed/23303884 http://dx.doi.org/10.1136/bmj.e7586 |
_version_ | 1782255365936644096 |
---|---|
author | Chan, An-Wen Tetzlaff, Jennifer M Gøtzsche, Peter C Altman, Douglas G Mann, Howard Berlin, Jesse A Dickersin, Kay Hróbjartsson, Asbjørn Schulz, Kenneth F Parulekar, Wendy R Krleža-Jerić, Karmela Laupacis, Andreas Moher, David |
author_facet | Chan, An-Wen Tetzlaff, Jennifer M Gøtzsche, Peter C Altman, Douglas G Mann, Howard Berlin, Jesse A Dickersin, Kay Hróbjartsson, Asbjørn Schulz, Kenneth F Parulekar, Wendy R Krleža-Jerić, Karmela Laupacis, Andreas Moher, David |
author_sort | Chan, An-Wen |
collection | PubMed |
description | High quality protocols facilitate proper conduct, reporting, and external review of clinical trials. However, the completeness of trial protocols is often inadequate. To help improve the content and quality of protocols, an international group of stakeholders developed the SPIRIT 2013 Statement (Standard Protocol Items: Recommendations for Interventional Trials). The SPIRIT Statement provides guidance in the form of a checklist of recommended items to include in a clinical trial protocol. This SPIRIT 2013 Explanation and Elaboration paper provides important information to promote full understanding of the checklist recommendations. For each checklist item, we provide a rationale and detailed description; a model example from an actual protocol; and relevant references supporting its importance. We strongly recommend that this explanatory paper be used in conjunction with the SPIRIT Statement. A website of resources is also available (www.spirit-statement.org). The SPIRIT 2013 Explanation and Elaboration paper, together with the Statement, should help with the drafting of trial protocols. Complete documentation of key trial elements can facilitate transparency and protocol review for the benefit of all stakeholders. |
format | Online Article Text |
id | pubmed-3541470 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BMJ Publishing Group Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-35414702013-01-10 SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials Chan, An-Wen Tetzlaff, Jennifer M Gøtzsche, Peter C Altman, Douglas G Mann, Howard Berlin, Jesse A Dickersin, Kay Hróbjartsson, Asbjørn Schulz, Kenneth F Parulekar, Wendy R Krleža-Jerić, Karmela Laupacis, Andreas Moher, David BMJ Research Methods & Reporting High quality protocols facilitate proper conduct, reporting, and external review of clinical trials. However, the completeness of trial protocols is often inadequate. To help improve the content and quality of protocols, an international group of stakeholders developed the SPIRIT 2013 Statement (Standard Protocol Items: Recommendations for Interventional Trials). The SPIRIT Statement provides guidance in the form of a checklist of recommended items to include in a clinical trial protocol. This SPIRIT 2013 Explanation and Elaboration paper provides important information to promote full understanding of the checklist recommendations. For each checklist item, we provide a rationale and detailed description; a model example from an actual protocol; and relevant references supporting its importance. We strongly recommend that this explanatory paper be used in conjunction with the SPIRIT Statement. A website of resources is also available (www.spirit-statement.org). The SPIRIT 2013 Explanation and Elaboration paper, together with the Statement, should help with the drafting of trial protocols. Complete documentation of key trial elements can facilitate transparency and protocol review for the benefit of all stakeholders. BMJ Publishing Group Ltd. 2013-01-09 /pmc/articles/PMC3541470/ /pubmed/23303884 http://dx.doi.org/10.1136/bmj.e7586 Text en © Chan et al 2013 This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode. |
spellingShingle | Research Methods & Reporting Chan, An-Wen Tetzlaff, Jennifer M Gøtzsche, Peter C Altman, Douglas G Mann, Howard Berlin, Jesse A Dickersin, Kay Hróbjartsson, Asbjørn Schulz, Kenneth F Parulekar, Wendy R Krleža-Jerić, Karmela Laupacis, Andreas Moher, David SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials |
title | SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials |
title_full | SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials |
title_fullStr | SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials |
title_full_unstemmed | SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials |
title_short | SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials |
title_sort | spirit 2013 explanation and elaboration: guidance for protocols of clinical trials |
topic | Research Methods & Reporting |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3541470/ https://www.ncbi.nlm.nih.gov/pubmed/23303884 http://dx.doi.org/10.1136/bmj.e7586 |
work_keys_str_mv | AT chananwen spirit2013explanationandelaborationguidanceforprotocolsofclinicaltrials AT tetzlaffjenniferm spirit2013explanationandelaborationguidanceforprotocolsofclinicaltrials AT gøtzschepeterc spirit2013explanationandelaborationguidanceforprotocolsofclinicaltrials AT altmandouglasg spirit2013explanationandelaborationguidanceforprotocolsofclinicaltrials AT mannhoward spirit2013explanationandelaborationguidanceforprotocolsofclinicaltrials AT berlinjessea spirit2013explanationandelaborationguidanceforprotocolsofclinicaltrials AT dickersinkay spirit2013explanationandelaborationguidanceforprotocolsofclinicaltrials AT hrobjartssonasbjørn spirit2013explanationandelaborationguidanceforprotocolsofclinicaltrials AT schulzkennethf spirit2013explanationandelaborationguidanceforprotocolsofclinicaltrials AT parulekarwendyr spirit2013explanationandelaborationguidanceforprotocolsofclinicaltrials AT krlezajerickarmela spirit2013explanationandelaborationguidanceforprotocolsofclinicaltrials AT laupacisandreas spirit2013explanationandelaborationguidanceforprotocolsofclinicaltrials AT moherdavid spirit2013explanationandelaborationguidanceforprotocolsofclinicaltrials |